SAS (Scandinavian Airlines) Improves Customer Service and Cuts Costs with Scandit’s Barcode Scanning on Smartphones
9.12.2019 10:00:00 EET | Business Wire | Press release
Scandit, the leading enterprise technology platform for mobile computer vision and augmented reality (AR), today announced that SAS (Scandinavian Airlines System) has integrated its powerful scanning software into their new Ground Handling App for smartphones, to replace expensive built-in scanners and upgrade critical ground workflows.
The mobile app (developed by Stockholm-based Objective Solutions) brings new efficiency and cost savings to workflows using mobile scanning of boarding passes, passports, meal vouchers and baggage tags. SAS has deployed the Scandit-powered app to their three Scandinavian airport hubs: Stockholm Arlanda, Oslo Gardermoen, and Copenhagen Kastrup. A detailed case study about the integration is now available.
SAS carries more than 30 million passengers annually to 120 destinations on over 170 aircraft and is widely recognized as a pioneer in digital innovation for the air travel industry. The Ground Handling App is part of a global, digital infrastructure initiative to streamline and improve key operations and improve the travelling experience for their growing volume of passengers. In the first deployment, SAS employees were equipped with 700 Galaxy A8 devices, with further rollouts planned across SAS’ global operations.
The Scandit software was easily integrated into the SAS IT ecosystem. Customer-facing SAS employees use the mobile app from anywhere in the airport, for example at the boarding gate where agents are no longer tied to gate podiums. Passengers are benefiting from a faster, more personalized service and SAS has reduced costs compared to the dedicated scanners and infrastructure. Booking changes can also be done seamlessly with the mobile app and baggage handlers use it to record and track baggage.
“We chose Scandit for its quality and flexibility,” said Fredrik Buxfeldt, Head of Digital Operations IT at SAS. “In addition to barcode scanning and OCR (optical character recognition) in mobile apps, Scandit also enables barcode scanning in websites, so our employees can also use mobile scanning from a browser if they don’t have the mobile app loaded.”
“SAS has reaped the benefits of modernizing data capture workflows with enterprise-grade mobile scanning,” said Samuel Mueller, CEO of Scandit. “We are delighted to play a part in this mobile evolution to help SAS meet its goals for outstanding customer service and operational efficiency.”
Resources
- View the SAS case study: https://www.scandit.com/resources/case-studies/sas/
- Learn more about Scandit’s air travel solutions: https://www.scandit.com/industries/air-travel/
- Download Scandit’s report (Fly High, One Mobile Scan at a Time) to learn how to innovate air travel with mobile computer vision and augmented reality: https://www.scandit.com/resources/whitepapers/fly-high-air-travel/
- Watch this video to see Scandit’s air travel solutions in action: https://www.scandit.com/resources/videos/air-travel-innovation-with-mobile-computer-vision/
- View Scandit’s press kit: https://www.scandit.com/press/
About Scandit
Scandit enables enterprises and consumers to change the way they interact with everyday objects and augment the physical world with real-time data captured by scanning barcodes and recognizing text, objects, and other visual identifiers using smartphones, tablets, wearables, drones, and robots.
Scandit’s mobile data capture platform is built on proprietary computer vision, augmented reality, and machine learning technologies. Companies in industries such as retail, transportation and logistics, manufacturing, and healthcare can use Scandit’s technology to create and power mobile apps for crucial enterprise workflows like search and find, shipping and receiving, inventory management, and proof of delivery.
Many of the world’s most innovative and successful companies are benefiting from Scandit’s enterprise-grade mobile data capture platform, including Alaska Airlines, FedEx, DHL, and PostNL.
For more information, visit https://www.scandit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191208005011/en/
Contact information
Brandon Watts
404-202-3476
brandon@wattsware.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom